Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight

Ilina Singh, Celia Morgan, Valerie Curran, David Nutt, Anne Schlag, Rupert McShane

Research output: Contribution to journalArticlepeer-review

103 Citations (Scopus)

Abstract

Summary We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical principles; however, clinicians and professional bodies must take steps to ensure that guidelines for good practice are enacted, that all experimental and trial data are made available through national registries, and that the risk potential of ketamine treatment continues to be monitored and modelled. We conclude with a set of key recommendations for oversight bodies that would support safe, effective, and ethical use of ketamine in depression.
Original languageEnglish
JournalThe Lancet Psychiatry
DOIs
Publication statusE-pub ahead of print - 5 Apr 2017

Fingerprint

Dive into the research topics of 'Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight'. Together they form a unique fingerprint.

Cite this